Edwards Lifesciences Corp (NYSE:EW) CEO Michael A. Mussallem sold 32,800 shares of the business’s stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $114.97, for a total transaction of $3,771,016.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Michael A. Mussallem also recently made the following trade(s):

  • On Tuesday, December 19th, Michael A. Mussallem sold 32,800 shares of Edwards Lifesciences stock. The stock was sold at an average price of $114.82, for a total transaction of $3,766,096.00.
  • On Monday, November 20th, Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences stock. The stock was sold at an average price of $106.86, for a total transaction of $3,515,694.00.
  • On Monday, October 30th, Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences stock. The stock was sold at an average price of $100.93, for a total transaction of $3,320,597.00.

Shares of Edwards Lifesciences Corp (NYSE EW) traded up $2.28 during midday trading on Monday, reaching $118.14. 1,263,656 shares of the company were exchanged, compared to its average volume of 1,344,680. The firm has a market cap of $25,000.00, a price-to-earnings ratio of 34.34, a PEG ratio of 1.86 and a beta of 0.51. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.76 and a current ratio of 3.49. Edwards Lifesciences Corp has a 12-month low of $86.55 and a 12-month high of $121.45.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.86 by ($0.02). Edwards Lifesciences had a return on equity of 27.22% and a net margin of 22.47%. The company had revenue of $821.50 million during the quarter, compared to analyst estimates of $833.85 million. During the same period in the previous year, the company posted $0.68 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 11.1% on a year-over-year basis. analysts expect that Edwards Lifesciences Corp will post 3.76 earnings per share for the current fiscal year.

Edwards Lifesciences announced that its Board of Directors has approved a stock repurchase program on Thursday, December 7th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the medical research company to repurchase shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Several research analysts recently weighed in on EW shares. Cowen set a $135.00 price objective on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research report on Sunday, December 10th. BMO Capital Markets reaffirmed a “buy” rating and set a $137.00 target price on shares of Edwards Lifesciences in a report on Friday, December 8th. Canaccord Genuity reaffirmed a “buy” rating and set a $137.00 target price on shares of Edwards Lifesciences in a report on Wednesday, November 29th. SunTrust Banks set a $124.00 target price on shares of Edwards Lifesciences and gave the stock a “buy” rating in a report on Wednesday, October 25th. Finally, Barclays lowered their target price on shares of Edwards Lifesciences from $120.00 to $118.00 and set an “equal weight” rating for the company in a report on Wednesday, October 25th. Six investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. Edwards Lifesciences currently has an average rating of “Buy” and an average target price of $129.57.

Large investors have recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in shares of Edwards Lifesciences by 2.0% in the 2nd quarter. Vanguard Group Inc. now owns 20,748,569 shares of the medical research company’s stock valued at $2,453,311,000 after purchasing an additional 406,901 shares during the period. BlackRock Inc. raised its holdings in shares of Edwards Lifesciences by 0.8% in the 2nd quarter. BlackRock Inc. now owns 14,109,514 shares of the medical research company’s stock valued at $1,668,309,000 after purchasing an additional 105,819 shares during the period. Wells Fargo & Company MN raised its holdings in shares of Edwards Lifesciences by 20.2% in the 3rd quarter. Wells Fargo & Company MN now owns 2,548,282 shares of the medical research company’s stock valued at $278,553,000 after purchasing an additional 429,022 shares during the period. American Century Companies Inc. raised its holdings in shares of Edwards Lifesciences by 7.0% in the 3rd quarter. American Century Companies Inc. now owns 2,224,010 shares of the medical research company’s stock valued at $243,107,000 after purchasing an additional 144,701 shares during the period. Finally, Artisan Partners Limited Partnership raised its holdings in shares of Edwards Lifesciences by 12.0% in the 3rd quarter. Artisan Partners Limited Partnership now owns 1,432,428 shares of the medical research company’s stock valued at $156,579,000 after purchasing an additional 153,896 shares during the period. 81.36% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Edwards Lifesciences Corp (EW) CEO Michael A. Mussallem Sells 32,800 Shares” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/08/edwards-lifesciences-corp-ew-ceo-michael-a-mussallem-sells-32800-shares-2.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.